Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MFN2 | O95140 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21045412 | 0.81 | MFN2 (1.00) | MFN2TSHRTAS1R3TAS1R1LMNA | |
| SCHEMBL20547940 | 0.78 | MFN2 (0.68) | MFN2POLBSMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL22315361 | 0.70 | MFN2 (0.77) | MFN2LMNAALDH1A1EPHX1L3MBTL1 | |
| SCHEMBL22404839 | 0.68 | MFN2 (0.65) | MFN2 | |
| SCHEMBL20547948 | 0.68 | MFN2 (0.65) | MFN2TSHRPOLBSMN1; SMN2TAS1R3 | |
| SCHEMBL21045483 | 0.68 | MFN2 (0.70) | MFN2TSHRSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL21045569 | 0.67 | MFN2 (0.54) | MFN2EPHX1 | |
| SCHEMBL21082494 | 0.67 | MFN2 (0.71) | MFN2TSHRTAS1R3TAS1R1LMNA | |
| SCHEMBL20548172 | 0.66 | MFN2 (0.52) | MFN2POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL21082415 | 0.65 | EPHX1 (0.51) | MFN2ALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11083699-B2 | Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof | MITOCHONDRIA EMOTION, INC. (US) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11083699-B2 | Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof | MFN2, TFB2M, HADHA | MFN2 1/4885TSHR 4251/4885POLB 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.